Biocon Sees Recovery In Biosimilars
Scope To Address Affordability In US As Mylan Partnership Bears Fruit
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.
